Pricing Log in Create free account
Friday 6 November 2026 Export TMO’s income statement to Excel — free account

Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.

Revenue
+9.13%
EPS
+8.64%
Free cash flow
+15.0%
Total debt
+22.8%

Quarter to September 2026, against a year earlier

679.52 26.64 −3.77%
Market cap
$250.8B
P/E
35.8×
Fwd P/E
35.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Thermo Fisher Scientific Inc. (TMO) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Oct 27, 2026 5.02 Departure or appointment of directors or officers Officer departure
10-Q Sep 26, 2026 P1I2: 6 added · 2 removed · 27 modified
P2I1A: no changes
8-K Oct 21, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 27, 2026 P1I2: 14 added · 4 removed · 13 modified
P2I1A: no changes
8-K Jul 23, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 20, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 28, 2026
8-K Apr 23, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Mar 24, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 1 added · 1 removed · 15 modified
1A: 2 added · 30 modified
7: 5 added · 7 removed · 33 modified
8-K Feb 9, 2026 1.01 Entry into a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 5.02 Departure or appointment of directors or officers
8-K Nov 24, 2025 1.01 Entry into a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 27, 2025
8-K Oct 29, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Oct 22, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 7, 2025 1.01 Entry into a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 1, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 28, 2025
8-K Jul 23, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 29, 2025
8-K Apr 23, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Jan 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 28, 2024
8-K Oct 23, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 29, 2024
8-K Jul 24, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 24, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 31, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.